VIDEO: Low-dose naltrexone shows promise in two patients with ‘complex’ refractory Crohn’s
Click Here to Manage Email Alerts
Though further study is warranted, Leonard B. Weinstock, MD, FACP, adjunct professor at the Washington University School of Medicine, reported promising results of low-dose naltrexone use among two patients with Crohn’s disease.
“This is a medication that is inexpensive, that has low risks and side effects, and generally, is something that you can add on with little regard to worrying about immunosuppression,” Weinstock said. “We have a study in the works for pediatric Crohn’s disease using LDN and we are looking for sites for patients to be enrolled.”
Editors note: After many invaluable comments and suggestions from our readers, this piece has been updated to reflect the small sample size and emphasize the need for more research on the efficacy of this drug.
Collapse
Weinstock LB. Abstract 3668472: Efficacy of low dose naltrexone in patients with Crohn’s colitis and ileitis. Presented at: Crohn’s and Colitis Congress; Jan. 20-22, 2022 (virtual meeting).
Click Here to Manage Email Alerts